# Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

> **NCT06462248** · PHASE2 · RECRUITING · sponsor: **Chi Kong Li** · enrollment: 20 (estimated)

## Conditions studied

- Lymphoma, Nonhodgkin
- Leukemia, Lymphocytic

## Interventions

- **DRUG:** CUCART19

## Key facts

- **NCT ID:** NCT06462248
- **Lead sponsor:** Chi Kong Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06462248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06462248, "Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06462248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*